Advertisement
UK markets close in 7 hours
  • FTSE 100

    8,058.16
    +34.29 (+0.43%)
     
  • FTSE 250

    19,690.52
    +91.13 (+0.46%)
     
  • AIM

    752.15
    +2.97 (+0.40%)
     
  • GBP/EUR

    1.1579
    -0.0010 (-0.08%)
     
  • GBP/USD

    1.2371
    +0.0020 (+0.17%)
     
  • Bitcoin GBP

    53,523.26
    -6.21 (-0.01%)
     
  • CMC Crypto 200

    1,391.09
    -23.67 (-1.67%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    82.75
    +0.85 (+1.04%)
     
  • GOLD FUTURES

    2,322.30
    -24.10 (-1.03%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    17,996.39
    +135.59 (+0.76%)
     
  • CAC 40

    8,065.08
    +24.72 (+0.31%)
     

Lynparza Could Be Merck’s Long-Term Growth Driver

Lynparza Could Be Merck’s Long-Term Growth Driver

Merck & Company (MRK) and AstraZeneca (AZN) jointly develop and commercialize Lynparza. In June, Merck and AstraZeneca presented data from the Study 08 trial, in which a combination of Lynparza and abiraterone demonstrated an improvement in median radiologic progression-free survival (or rPFS) compared to abiraterone monotherapy.